Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Gains from Investment Securities (2016 - 2025)

Apyx Medical's Gains from Investment Securities history spans 12 years, with the latest figure at -$99000.0 for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 55.8% year-over-year to -$99000.0; the TTM value through Dec 2025 reached -$292000.0, down 10.19%, while the annual FY2025 figure was $1.6 million, 3.4% up from the prior year.
  • Gains from Investment Securities reached -$99000.0 in Q4 2025 per APYX's latest filing, down from $1.1 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $8.6 million in Q2 2025 to a low of -$2.4 million in Q3 2023.
  • Average Gains from Investment Securities over 4 years is $1.1 million, with a median of -$9500.0 recorded in 2022.
  • Peak YoY movement for Gains from Investment Securities: plummeted 8282.76% in 2023, then soared 28503.66% in 2025.
  • A 4-year view of Gains from Investment Securities shows it stood at $1000.0 in 2022, then plummeted by 5200.0% to -$51000.0 in 2023, then tumbled by 339.22% to -$224000.0 in 2024, then skyrocketed by 55.8% to -$99000.0 in 2025.
  • Per Business Quant, the three most recent readings for APYX's Gains from Investment Securities are -$99000.0 (Q4 2025), $1.1 million (Q3 2025), and $8.6 million (Q2 2025).